As of 2025-09-17, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -5.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 2,664.68 mil USD. RARE's TTM EBITDA according to its financial statements is -526.82 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.4x - 13.4x | 12.9x |
| Forward P/E multiples | 19.1x - 43.4x | 31.2x |
| Fair Price | (102.58) - (71.42) | (118.85) |
| Upside | -448.0% - -342.3% | -503.1% |
| Date | EV/EBITDA |
| 2025-09-16 | -5.06 |
| 2025-09-15 | -4.97 |
| 2025-09-12 | -5.21 |
| 2025-09-11 | -5.38 |
| 2025-09-10 | -5.39 |
| 2025-09-09 | -5.43 |
| 2025-09-08 | -5.43 |
| 2025-09-05 | -5.49 |
| 2025-09-04 | -5.39 |
| 2025-09-03 | -5.44 |
| 2025-09-02 | -5.52 |
| 2025-08-29 | -5.15 |
| 2025-08-28 | -5.21 |
| 2025-08-27 | -5.17 |
| 2025-08-26 | -5.07 |
| 2025-08-25 | -5.02 |
| 2025-08-22 | -5.11 |
| 2025-08-21 | -5.07 |
| 2025-08-20 | -5.04 |
| 2025-08-19 | -4.99 |
| 2025-08-18 | -5.10 |
| 2025-08-15 | -5.10 |
| 2025-08-14 | -4.97 |
| 2025-08-13 | -4.96 |
| 2025-08-12 | -4.81 |
| 2025-08-11 | -4.68 |
| 2025-08-08 | -4.70 |
| 2025-08-07 | -4.76 |
| 2025-08-06 | -4.80 |
| 2025-08-05 | -4.96 |
| 2025-08-04 | -4.87 |
| 2025-08-01 | -4.87 |
| 2025-07-31 | -4.66 |
| 2025-07-30 | -4.63 |
| 2025-07-29 | -4.73 |
| 2025-07-28 | -4.72 |
| 2025-07-25 | -4.67 |
| 2025-07-24 | -4.66 |
| 2025-07-23 | -4.79 |
| 2025-07-22 | -4.50 |
| 2025-07-21 | -4.49 |
| 2025-07-18 | -4.48 |
| 2025-07-17 | -4.68 |
| 2025-07-16 | -4.66 |
| 2025-07-15 | -4.64 |
| 2025-07-14 | -5.01 |
| 2025-07-11 | -5.06 |
| 2025-07-10 | -5.34 |
| 2025-07-09 | -7.25 |
| 2025-07-08 | -6.88 |